Current applications and future needs for biomarkers in pediatric cardiomyopathy and heart failure: Summary from the Second International Conference on Pediatric Cardiomyopathy

Progress in Pediatric Cardiology

Volumn 32, Issue 1, 2011, Pages 11-14

  Kantor, Paul F ^a   Rusconi, Paolo ^b   Lipshultz, Steven ^b   Mital, Seema ^a   Wilkinson, James D ^b   Burch, Michael ^c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biological markers; Cardiomyopathy; Heart failure; Pediatric; Ventricular remodeling

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; MIDREGION A TYPE NATRIURETIC PEPTIDE; MIDREGION ADRENOMEDULLIN; PROCOLLAGEN 1; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; GENETIC RISK; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LUNG ARTERY PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SUDDEN DEATH;

EID: 79961165951     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2011.06.003     Document Type: Article

References (39)

1. Morrow D.A., de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115:949-952.
2. Mir T.S., Laux R., Hellwege H.H., et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 2003, 112:896-899.
3. Nir A., Nasser N. Clinical value of NT-ProBNP and BNP in pediatric cardiology. J Card Fail 2005, 11:S76-S80.
4. Mir T.S., Marohn S., Laer S., Eiselt M., Grollmus O., Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002, 110:e76.
5. Nir A., Bar-Oz B., Perles Z., Brooks R., Korach A., Rein A.J. N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 2004, 93:603-607.
6. Cohen S., Springer C., Avital A., et al. Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease in pediatric respiratory distress?. Pediatrics 2005, 115:1347-1350.
7. Geiger R., Hammerer-Lercher A., Url C., et al. NT-proBNP concentrations indicate cardiac disease in pediatric patients. Int J Cardiol 2007, 123:63-65.
8. Niedner M.F., Foley J.L., Riffenburgh R.H., Bichell D.P., Peterson B.M., Rodarte A. B-type natriuretic peptide: perioperative patterns in congenital heart disease. Congenit Heart Dis 2010 May-Jun, 5(3):243-255.
9. Hammerer-Lercher A., Geiger R., Mair J., et al. Utility of N-terminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac diseases in young pediatric patients. Clin Chem 2006, 52:1415-1419.
10. Mangat J., Carter C., Riley G., Foo Y., Burch M. The clinical utility of brain natriuretic peptide in paediatric left ventricular failure. Eur J Heart Fail 2009, 11:48-52.
11. Wong D.T., George K., Wilson J., Manlhiot C., McCrindle B.W., Adeli K., Kantor P.F. Effectiveness of serial increases in amino-terminal pro-B-type natriuretic peptide levels to indicate the need for mechanical circulatory support in children with acute decompensated heart failure. Am J Cardiol 2011 Feb 15, 107(4):573-578.
12. Law Y.M., Hoyer A.W., Reller M.D., Silberbach M. Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study. J Am Coll Cardiol 2009, 54:1467-1475.
13. Koulouri S., Acherman R.J., Wong P.C., Chan L.S., Lewis A.B. Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol 2004, 25:341-346.
14. Suda K., Matsumura M., Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003, 45:249-254.
15. Kunii Y., Kamada M., Ohtsuki S., et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 2003, 57:191-197.
16. Price J.F., Thomas A.K., Grenier M., et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 2006, 114:1063-1069.
17. Rusconi P L.D., Ratnasamy C., Mas R., Harmon W.G., Colan S.D., Lipshultz S.E. Serial Measurements of Serum NT-proBNP as Markers of Left Ventricular Systolic Function and Remodeling in Children with Heart Failure. Am Heart J 2010 Oct, 160(4):776-783.
18. Omland T., de Lemos J.A., Sabatine M.S., et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009, 361:2538-2547.
19. Orea-Tejeda A D.T., Sanchez-Gonzalez LR K., Castillo-Martinez L J., et al. Prognostic value of cardiac troponin T elevation is independent of renal function and clinical findings in heart failure patients. Cardiol J 2010, 17(1):42-48.
20. Tsutamoto T., Kawahara C., Nishiyama K. Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure. Am Heart J 2010 Jan, 159(1):63-67.
21. Mueller C., Laule-Kilian K., Christ A., Brunner-La Rocca H.P., Perruchoud A.P. Inflammation and long-term mortality in acute congestive heart failure. Am Heart J 2006, 151:845-850.
22. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003, 107:1486-1491.
23. Kardys I., Knetsch A.M., Bleumink G.S., et al. C-reactive protein and risk of heart failure. The Rotterdam Study. Am Heart J 2006, 152:514-520.
24. Ratnasamy C., Kinnamon D.D., Lipshultz S.E., Rusconi P. Associations between neurohormonal and inflammatory activation and heart failure in children. Am Heart J 2008, 155:527-533.
25. Mohapatra B., Vick G.W., Fraser C.D., et al. Short-term mechanical unloading and reverse remodeling of failing hearts in children. J Heart Lung Transplant 2010, 29:98-104.
26. de Boer R.A., Voors A.A., Muntendam P., van Gilst W.H., van Veldhuisen D.J. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009, 11:811-817.
27. Shah R.V., Chen-Tournoux A.A., Picard M.H., van Kimmenade R.R., Januzzi J.L. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009, 2:311-319.
28. Pascual-Figal D.A., Ordonez-Llanos J., Tornel P.L., et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009, 54:2174-2179.
29. Januzzi J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007, 50:607-613.
30. Daniels L.B., Clopton P., Iqbal N., Tran K., Maisel A.S. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J 2010 Oct, 160(4):721-728.
31. Wollert K.C., Kempf T., Peter T., et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007, 115:962-971.
32. Khan S.Q., Ng K., Dhillon O., et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J 2009, 30:1057-1065.
33. Querejeta R., Varo N., Lopez B., et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000, 101:1729-1735.
34. King M.K., Coker M.L., Goldberg A., et al. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res 2003, 92:177-185.
35. Udelson J.E., Feldman A.M., Greenberg B., et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail 2010, 3:347-353.
36. Martos R., Baugh J., Ledwidge M., et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007, 115:888-895.
37. Babu-Narayan S.V., Kilner P.J., Li W., et al. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of fallot and its relationship to adverse markers of clinical outcome. Circulation 2006, 113:405-413.
38. Shirani J., Pick R., Roberts W.C., Maron B.J. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000, 35:36-44.
39. Ho C.Y., Lopez B., Coelho-Filho O.R., et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010, 363:552-563.